GlassScriptPhysician profile
James Daniel Hill
NPI 1013438969
$4,228.38
in general payments reported to CMS, 2019-2025
35 companies · $776 in 2025
The $776 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $215 · 2022: $658 · 2023: $1,293 · 2024: $1,287 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,336 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,336.23 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $544.90 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $515.26 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $371.69 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $304.92 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.92 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $182.60 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Harmony Biosciences LLC | $171.47 | 2023-2025 | Wakix |
| Merck Sharp & Dohme LLC | $163.81 | 2022-2024 | Verquvo, Belsomra, Steglatro |
| Abbvie INC. | $163.42 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.89 | 2021-2025 | Xifaxan |
| Exact Sciences Corporation | $141.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $138.57 | 2022-2024 | Caplyta |
| Amgen INC. | $127.40 | 2021-2025 | Repatha, Otezla, Repatha |
| Axsome Therapeutics, INC. | $127.11 | 2024-2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $92.28 | 2022-2024 | Seglentis, Livalo, Zoryve |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $81.95 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $68.46 | 2023 | Quviviq |
| Dexcom, INC. | $67.10 | 2021-2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $62.85 | 2022-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $61.54 | 2021-2023 | Eliquis |
| Pfizer INC. | $59.71 | 2022-2024 | |
| Corium, LLC | $51.47 | 2023-2024 | Azstarys |
| Verona Pharma, INC. | $49.48 | 2025 | Ohtuvayre |
| Lundbeck LLC | $46.80 | 2022-2025 | Rexulti |
| Amarin Pharma, INC. | $37.88 | 2022 | |
| Supernus Pharmaceuticals, INC. | $31.30 | 2024-2025 | Qelbree |
| Athena Bioscience, LLC | $23.33 | 2024 | Qdolo |
| Biogen, INC. | $22.79 | 2023 | Skyclarys |
| Esperion Therapeutics, INC. | $21.52 | 2023 | Nexletol |
| Vertex Pharmaceuticals Incorporated | $20.27 | 2025 | |
| Paratek Pharmaceuticals, INC. | $19.61 | 2024 | Nuzyra |
| Radius Health, INC. | $16.36 | 2025 | |
| Phathom Pharmaceuticals, INC. | $16.06 | 2023 | Voquezna |
| Ironshore Pharmaceuticals INC. | $14.88 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.